Payment overview · 2025
General Payments
$446.91
18 reported records · 12 companies
Healthcare provider profile · identity verified
Robert Paul Snyder, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · INDIANA, PA · NPI 1932598414
Verified facts
What the public records show
CMS Open Payments records show Robert Paul Snyder, D.O. received $446.91 in general payments during 2025 across 18 reported records.
Medtronic, Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$88.60 | 19.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.38 | 15.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.50 | 12.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.24 | 11.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.40 | 8.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.14 | 7.9% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.34 | 5.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.63 | 4.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.82 | 4.2% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.15 | 4.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.01 | 3.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.70 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $446.91 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $88.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $35.14 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 48 |
| Omeprazole | Omeprazole | 170 | 48 |
| Furosemide | Furosemide | 155 | 45 |
| Gabapentin | Gabapentin | 152 | 33 |
| Lisinopril | Lisinopril | 143 | 39 |
| Losartan Potassium | Losartan Potassium | 137 | 43 |
| Meloxicam | Meloxicam | 129 | 36 |
| Prednisone | Prednisone | 114 | 71 |
| Famotidine | Famotidine | 112 | 40 |
| Potassium Chloride | Potassium Chloride | 108 | 30 |
| Metformin Hcl | Metformin Hcl | 107 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 19 |
| Bupropion Xl | Bupropion Hcl | 73 | 13 |
| Sertraline Hcl | Sertraline Hcl | 72 | 22 |
| Mirtazapine | Mirtazapine | 71 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 20 |
| Tramadol Hcl | Tramadol Hcl | 59 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Simvastatin | Simvastatin | 56 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Clonazepam | Clonazepam | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 13 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 12 |
| Ozempic | Semaglutide | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | 11 |
| Sucralfate | Sucralfate | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Finasteride | Finasteride | 30 | 12 |
| Methylprednisolone | Methylprednisolone | 30 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Azithromycin | Azithromycin | 27 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Baclofen | Baclofen | 16 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $446.91 · 18 records | Medtronic, Inc. | Auvelity, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, FANAPT, INCEPTIV, Ozempic, QULIPTA, Rybelsus, SMARTVEST, SPINRAZA, TRINTELLIX, UBRELVY, VIVITROL, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error